Cost-effectiveness of Lung Cancer Screening in Canada

被引:83
作者
Goffin, John R. [1 ]
Flanagan, William M. [2 ]
Miller, Anthony B. [3 ]
Fitzgerald, Natalie R. [4 ]
Memon, Saima [4 ]
Wolfson, Michael C. [5 ]
Evans, William K. [1 ]
机构
[1] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[2] Stat Canada, Ottawa, ON, Canada
[3] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[4] Canadian Partnership Canc, Toronto, ON, Canada
[5] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada
关键词
COMPUTED-TOMOGRAPHY; SOCIOECONOMIC-STATUS; CT; RISK; MANAGEMENT; SMOKERS; PREDICTION; MORTALITY;
D O I
10.1001/jamaoncol.2015.2472
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE The US National Lung Screening Trial supports screening for lung cancer among smokers using low-dose computed tomographic (LDCT) scans. The cost-effectiveness of screening in a publically funded health care system remains a concern. OBJECTIVE To assess the cost-effectiveness of LDCT scan screening for lung cancer within the Canadian health care system. DESIGN, SETTING, AND PARTICIPANTS The Cancer Risk Management Model (CRMM) simulated individual lives within the Canadian population from 2014 to 2034, incorporating cancer risk, disease management, outcome, and cost data. Smokers and former smokers eligible for lung cancer screening (30 pack-year smoking history, ages 55-74 years, for the reference scenario) were modeled, and performance parameters were calibrated to the National Lung Screening Trial (NLST). The reference screening scenario assumes annual scans to age 75 years, 60% participation by 10 years, 70% adherence to screening, and unchanged smoking rates. The CRMM outputs are aggregated, and costs (2008 Canadian dollars) and life-years are discounted 3% annually. MAIN OUTCOMES AND MEASURES The incremental cost-effectiveness ratio. RESULTS Compared with no screening, the reference scenario saved 51 000 quality-adjusted life-years (QALY) and had an incremental cost-effectiveness ratio of CaD $52 000/QALY. If smoking history is modeled for 20 or 40 pack-years, incremental cost-effectiveness ratios of CaD $62 000 and CaD $43 000/QALY, respectively, were generated. Changes in participation rates altered life years saved but not the incremental cost-effectiveness ratio, while the incremental cost-effectiveness ratio is sensitive to changes in adherence. An adjunct smoking cessation program improving the quit rate by 22.5% improves the incremental cost-effectiveness ratio to CaD $24 000/QALY. CONCLUSIONS AND RELEVANCE Lung cancer screening with LDCT appears cost-effective in the publicly funded Canadian health care system. An adjunct smoking cessation program has the potential to improve outcomes.
引用
收藏
页码:807 / 813
页数:7
相关论文
共 51 条
  • [1] Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
    Aberle, Denise R.
    Adams, Amanda M.
    Berg, Christine D.
    Black, William C.
    Clapp, Jonathan D.
    Fagerstrom, Richard M.
    Gareen, Ilana F.
    Gatsonis, Constantine
    Marcus, Pamela M.
    Sicks, JoRean D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (05) : 395 - 409
  • [2] [Anonymous], 2015, COST EFF STRAT PLANN
  • [3] [Anonymous], 2013, Canadian Cancer Statistics 2013
  • [4] [Anonymous], 2014, NAT HLTH EXP TRENDS
  • [5] Benefits and Harms of CT Screening for Lung Cancer A Systematic Review
    Bach, Peter B.
    Mirkin, Joshua N.
    Oliver, Thomas K.
    Azzoli, Christopher G.
    Berry, Donald A.
    Brawley, Otis W.
    Byers, Tim
    Colditz, Graham A.
    Gould, Michael K.
    Jett, James R.
    Sabichi, Anita L.
    Smith-Bindman, Rebecca
    Wood, Douglas E.
    Qaseem, Amir
    Detterbeck, Frank C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (22): : 2418 - 2429
  • [6] Birch Stephen, 2006, J Health Serv Res Policy, V11, P46, DOI 10.1258/135581906775094235
  • [7] Cost-Effectiveness of CT Screening in the National Lung Screening Trial
    Black, William C.
    Gareen, Ilana F.
    Soneji, Samir S.
    Sicks, JoRean D.
    Keeler, Emmett B.
    Aberle, Denise R.
    Naeim, Arash
    Church, Timothy R.
    Silvestri, Gerard A.
    Gorelick, Jeremy
    Gatsonis, Constantine
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) : 1793 - 1802
  • [8] Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
    Butts, Charles A.
    Ding, Keyue
    Seymour, Lesley
    Twumasi-Ankrah, Philip
    Graham, Barbara
    Gandara, David
    Johnson, David H.
    Kesler, Kenneth A.
    Green, Mark
    Vincent, Mark
    Cormier, Yvon
    Goss, Glenwood
    Findlay, Brian
    Johnston, Michael
    Tsao, Ming-Sound
    Shepherd, Frances A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 29 - 34
  • [9] Canadian Partnership Against Canada, 2011, LUNG CANC CAN SUPPL
  • [10] Canadian Partnership Against Cancer, 2012, BREAST CANC CONTR CA